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Chlamydia infection of the cardiovascular system is associated with pericarditis, endocarditis and myocarditis. 
Chlamydia particles can also be observed in damaged heart valves. There is now good evidence that the lesions of 
arteriosclerosis and aortic aneurysm as well as valvular disease may be associated with C. pneumoniae infection. 
Patients with acute myocardial infarction show seroconversion against Chlamydia lipopolysaccharide. In a prospective 
study of 4000 healthy hypercholesterolemic men, signs suggestive of chronic C. pneumoniae infection increased the risk 
of a cardiac event three-fold. This risk factor is synergistic with the smoking risk. lmmunohistochemistry also 
demonstrated Chlamydia lipopolysaccharide in samples of aortic aneurysm. Chlamydia1 inflammation may play a role 
in the oxidation of low density lipoprotein in atherosclerotic lesions. 
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Acute diseases of the endocardium and blood vessels 
caused by intracellular pathogens include endocarditis, 
thrombophlebitis, infective endocarditis and infective 
aneurism. Myocarditis is most often caused by intra- 
cellular viruses. Pericardtis is a cligical entity found 
often in connection with other inflammation. Intra- 
cellular pathogens have been associated with abdominal 
aortic aneurisms, arteriosclerosis and cardiomyopathy, 
though evidence on cardiomyopathy is meagre at this 
moment. 
INTRACELLUIAR BACTERIA IN CARDIOVASCULAR 
DISEASE 
Intracellular bacteria have been a neglected chapter in 
cardiovascular disease. This is due to difficulties in 
diagnostic procedures. Intracellular bacteria do not 
appear in blood cultures. Isolation demands living 
cells and considerable expertise. Few laboratories 
performing serologic tests are able to find them. The 
polymerase chain reaction (PCR) and other nucleic 
acid multiplication methods could perhaps be the 
answer but are not available so far. The main intra- 
cellular bacteria associated with cardiovascular diseases 
found outside the tropics are three species of Chlamydia, 
Coxiella burnetii and numerous other Rickettsia species. 
I will concentrate on Chlamydia. 
Unlike Rickettsia, Chlamydia in the cardiovascular 
system seems not to be disseminated by blood-sucking 
arthropods. In the past, the usual way to isolate the 
agent was to inoculate experimental animals and then 
to show at autopsy the presence of elementary bodes 
in the pericardial fluid. Chlamydia psittaci has been 
known to cause various cardiovascular diseases. Besides 
pericarditis it also causes endo- and myocarditis. The 
exact role of Chlamydiapsittaci disease in valvular lesions 
is unknown. In the 1930s pulmonary embolism was 
reported to be common in psittacosis, and later studies 
have shown these emboli to be filled with Chlamydia 
particles [l]. 
The best example of the involvement of Chlamydia 
in cardiovascular diseases is the report in 1974 of 
Chlamydia particles in a considerable number of 
damaged heart valves [2]. To my knowledge this report 
led to no response among cardiologists or even 
infectious diseases specialists. Eighteen years later a 
French publication reported the fkequent presence of 
chlamydial antigen in damaged heart valves [3], but I 
seriously doubt if it has led to  any alterations in the 
treatment of valvular disease. The Seattle group of 
Grayston described cases of myocarditis in children 
obviously caused by Chlamydia trachomatic [4]. One of 
the cases led to progressive cardomyopathy and death. 
The observation of Chlamydia infection in childhood 
myocarditis has been subsequently confirmed [5]. 
Although Chlamydia pneumoniae was first reported only 
10 years ago, it too has already been associated with 
endocarditis and myocarditis. Thls myocarditis is so 
insidious and the symptoms so mild and so prolonged 
in course that an athlete can return to training although 
there is a possibility of a smal l ,  fatal, inflammatory focus 
in the heart valve [6]. 
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CHLAMYDIA AND ATHEROSCLEROTIC DISEASE 
Chlamydia pneumoniae is associated with chronic 
cardiovascular inflammations like arteriosclerosis, ab- 
dominal aortic aneurisms and valvular lesions. The first 
indication of t h i s  association was the finding that nearly 
70% of acute myocardial lnfarction patients showed 
seroconversion against Chlamydia lipopolysaccharide 
(LPS) [7]. In microimmunofluorescence titration we 
have found that acute myocardial infarction (AMI) 
patients did not show the seroconversion seen in acute 
Chlamydia pneumoniae infection but showed steady 
elevated titers. Moreover, these titers were found in 
patients with chronic coronary heart disease (CCHD) 
(Table 1). This led us to suggest that CCHD is 
associated with chronic C. pneumoniae infection, and 
that in AM1 there is an acute exacerbation of t h i s  
infection. We later found that the seroconversion 
against Chlamydia LPS seems to be due to an imbalance 
in immune complexes [8]. 
To exclude the possibhty that coronary heart 
disease only makes patients more susceptible to C. 
pneumoniae infection, we performed a prospective study 
in connection with the Helsirh Heart Study [9]. Some 
4000 healthy hypercholesterolemic men were treated 
with a cholesterol-lowering drug or placebo and 
followed for 5 years. We determined the odds ratios 
predicting the possibility of suffering a cardiac event 3 
to 6 months later. We found that if these healthy men 
had signs suggestive of a chronic C. pneumoniae 
infection (namely elevated IgA antibody titers, or im- 
munocomplexes containing' Chlamydia LPS) then they 
had a nearly three-fold risk of a cardiac event later on. 
The new risk factor was independent of established 
ones but synergistic with two factors, age and smoking. 
Figure 1 shows the association with smoking. The odds 
ratio for non-smokers without markers of chronic C. 
pneumoniae infection was estimated as 1. Smoking 
without markers of C. pneumoniae raised hs risk to 
2.64. Markers of C. pneumoniae alone caused higher risk 
than smoking, and markers suggestive of C. pneumoniae 
Table 1 Serologic evidence of an association of a novel 
Chlamydia, WAR, with chronic coronary heart disease 
(CCHD) and acute myocardial infarction ( M I )  
~ ~~ ~ 
C. pneumoniae AM1 CCHD Control pvaluc* 
antibody parameter ('A) (%) 04 (s/o) 
IgG 2128 50 47 15 <0.001 
IgA 2 32 45 37 10 -=O.OOl 
Combined 68 50 17 <O.Ool 
LPS seroconversion 68 0 1 <0.001 
*AM1 versus controls. 
From Saikku et al. [7] 
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SMOKING AND MARKERS OF CPN 
Figure 1 Odds ratio for a cardiac event rclated to smoking 
and markers of C. pneumoniae infection. (Saikku et al, 
unpublished observations.) 
infection in non-smokers raised the risk four-fold. 
Both risk factors together raised the risk for cardiac 
event nearly six-fold. Our observation of the 
serological association was first confirmed in Seattle and 
later on in Sweden, the UK, Germany and the 
Netherlands. We tried in vain to get pathologists 
interested in these associations [1&17]. 
PATHOGENETIC MECHANISMS 
Sections fiPm arteriosclerotic lesions may show foam 
cells, the key cells in the pathogenesis of arteriosclerosis, 
to be filled with unusual particles. These have always 
been seen by electron microscopists in arteriosclerosis 
plaques. But Shor was the first to realize that they might 
be C. pneumoniae particles and Grayston's group 
confirmed that this was the case [18]. They used several 
methods and now it is firmly established that C. 
pneumoniae particles are fi-equent in arteriosclerosic 
plaques but are not found in healthy areas [19-251. 
It is Wicult to get adequate samples h m  arterio- 
slerotic plaques or coronary arteries, but abdominal 
aortic aneurysms provide an alternative. They tend to 
occur in elderly people who are usually smokers, 
arteriosclerotic, male, and have chronic bronchitis. The 
excised areas provide ample material for study. Using 
immunohistochemistry we were able to detect 
Chlamydia LPS in all samples, and in a majority also saw 
C. pneumoniae-specific proteins. All test samples were 
positive for C. pneumoniae PCR as well. Chlamydia 
could be seen in electron microscopy. All patients, 
however, were not positive in the microimmuno- 
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Table 2 Lipid parameters in Aurora Hospital (Finland) 
pneumonia 
C. pneumoniae S. pneumoniae Virus 
Lipid parameter (n=17) (n=22) (n=14) 
Cholesterol 3.8 rt 0.9 3.3 2 1.0 4.1 -C 1.3 
Triglycerides 2.4 k 0.7 1.5 -C 0.7 1.7 A 0.7 
HDL 0.6 rt 0.3 0.8 2 0.4 0.9 2 0.3 
HDLz 0.06 f 0.04 0.16 2 0.12 0.17 ? 0.09 
Leionen et al, unpublished observations. 
fluorescence test. This is a phenomenon earlier noted 
by Grayston’s group and so far we do not know the 
mechanism underlying t h  finding. 
The generally accepted view is that in arterio- 
sclerosis there is a strong inflammatory component. 
Because low-density lipoproteins (LDLs) found in the 
lesion are oxidized, the current hypothesis is that thu 
oxidned LDL causes the inflammation. Could it be, 
however, that the inflammation is oxidizing the 
deposited LDL in arteriosclerotic lesions? Chronic 
idammation would be the initiator of the process and 
cholesterol deposition would be an indicator of it. We 
do not know so far, but &IS hypothesis should be 
studied. 
In some recent studies it has been clauned that a 
combination of elevated triglycerides and lowered 
HDL cholesterol is the best predictor of coronary heart 
disease. In this light, lipid parameters were followed 
in pneumonias caused by S. pneumoniae, viruses or C. 
pneumoniae. In C. pneumoniae infections triglycerides 
were elevated and HDL lowered (Table 2). Whether 
this is also happening in chronic C. pneumohiae 
infections we do not know. Nor do we know the role 
of C. pneumoniae particles found in arteriosclerotic 
lesions. But it is interesting to speculate that they are 
capable of causing various phenomena associated with 
this serious hsease. 
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